Ulcerative Colitis Clinical Pipeline | 70+ Companies Pioneering the Next Breakthroughs

The ulcerative colitis market is undergoing a transformative shift, driven by cutting-edge research and innovative therapies.

DelveInsight's 'Ulcerative Colitis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Ulcerative Colitis therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Ulcerative Colitis pipeline domain.

For Ulcerative Colitis emerging drugs, the Ulcerative Colitis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Ulcerative Colitis Pipeline Report
• DelveInsight's Ulcerative Colitis Pipeline analysis depicts a robust space with 70+ active players working to develop 75+ pipeline drugs for Ulcerative Colitis treatment.
• The leading Ulcerative Colitis companies include Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others are evaluating their lead assets to improve the Ulcerative Colitis treatment landscape.
• Key Ulcerative Colitis pipeline therapies in various stages of development include Etrasimod, Description, Ivarmacitinib, Cobitolimod, TREMFYA, Omilancor, PRA023, Remestemcel-L, ritlecitinib, brepocitinib, ABBV-668, TEV-48574, SOR102, and others.
• In December 2024, Celltrion announced that the FDA approved STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), for subcutaneous injection or intravenous infusion. It is approved for adult and pediatric patients with plaque psoriasis and psoriatic arthritis, as well as adult patients with Crohn's disease and ulcerative colitis.
• In December 2024, Accropeutics Inc. announced FDA clearance for a Phase II trial of its RIPK2 inhibitor, AC-101, for moderate-to-severe Ulcerative Colitis. The 12-week, multi-regional, randomized trial will assess its safety and efficacy.
• On October 7, 2024, Spherix Global Insights reported that AbbVie's Skyrizi has rapidly outpaced Eli Lilly's Omvoh in the ulcerative colitis market, securing over double the market share of its competitor just two months post-launch. However, AbbVie is now confronted with a new competitor, as Spherix anticipates a similarly swift market entry for Johnson & Johnson's Tremfya.

Request a sample and discover the recent breakthroughs happening in the Ulcerative Colitis pipeline landscape @ https://www.delveinsight.com/report-store/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Ulcerative Colitis Overview
Ulcerative colitis is a chronic inflammatory disease of the colon, characterized by diffuse friability and superficial erosions on the colonic wall, often leading to bleeding. It is the most prevalent form of inflammatory bowel disease worldwide, typically beginning in the rect*m and spreading proximally in a continuous pattern. Unlike other inflammatory conditions, ulcerative colitis is confined to the mucosa and submucosa of the colon. The exact cause remains unknown, but genetics play a significant role, with family history being the strongest independent risk factor. Individuals with a first-degree relative affected by ulcerative colitis are at a fourfold higher risk, and the condition is notably more common in Jewish populations. In the United States alone, the disease leads to hundreds of thousands of medical visits annually, with direct healthcare costs exceeding four billion dollars.

The pathophysiology of ulcerative colitis involves complex interactions between epithelial barrier defects, immune system dysregulation, leukocyte recruitment abnormalities, and the intestinal microbiome. Disruptions in the colonic mucin layer and tight junctions compromise the epithelial barrier, allowing excessive uptake of luminal antigens. The immune system is also hyperactive, with an overabundance of activated dendritic cells expressing toll-like receptors (TLR2 and TLR4), leading to an atypical T-helper 2 (Th2) response that damages epithelial cells. Additionally, leukocyte recruitment is heightened due to increased levels of the chemoattractant CXCL8 and the adhesion molecule Mad-CAM1, facilitating excessive immune cell infiltration into mucosal tissue. Studies suggest that an imbalance between the gut microbiome and mucosal immunity contributes to the disease, with an abnormal immune response targeting non-pathogenic bacteria, further driving inflammation.

Find out more about Ulcerative Colitis medication @ https://www.delveinsight.com/report-store/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Ulcerative Colitis Treatment Analysis: Drug Profile
Obefazimod: Abivax
Obefazimod is an oral small-molecule drug candidate in advanced clinical development for the treatment of moderate to severe ulcerative colitis (UC). It has demonstrated significant anti-inflammatory activity in both preclinical studies and clinical trials, including Phase IIa and Phase IIb studies. Currently, Obefazimod is progressing through Phase III trials for ulcerative colitis.

ABBV-668: AbbVie
ABBV-668 is an investigational therapy being developed for ulcerative colitis, Crohn's disease, and other unspecified immunological disorders. The drug targets receptor-interacting serine/threonine protein kinase 1 (RIPK1), a key player in inflammatory pathways. Administered orally, ABBV-668 is currently in Phase II clinical trials for ulcerative colitis.

TEV-48574: Teva Pharmaceuticals
TEV-48574 (Anti-TL1A) is a human IgG1 monoclonal antibody designed to target tumor necrosis factor (TNF)-like ligand 1A (TL1A), a key driver of inflammation and fibrosis in inflammatory bowel disease (IBD). By inhibiting TL1A signaling, TEV-48574 aims to modulate immune responses in conditions such as ulcerative colitis (UC) and Crohn's disease (CD). Currently, the drug is in Phase IIb clinical trials for UC, though its safety and efficacy remain under regulatory review.

Key Ulcerative Colitis Therapies and Companies
• Etrasimod (APD334): Arena Pharmaceuticals/Pfizer
• ABX464 (Obefazimod): Abivax
• SHR0302 (Ivarmacitinib): Reistone Biopharma
• Cobitolimod: InDex Pharmaceuticals
• TREMFYA (Guselkumab): Janssen Pharmaceuticals
• BT-11 (Omilancor): Landos Biopharma/NImmune
• PRA023: Merck
• Remestemcel-L: Mesoblast
• PF-06651600 (ritlecitinib) and PF-06700841 (brepocitinib): Pfizer
• ABBV-668: AbbVie
• TEV-48574: Teva Pharmaceutical
• SOR102: Sorriso Pharmaceuticals

Learn more about the novel and emerging Ulcerative Colitis pipeline therapies @ https://www.delveinsight.com/report-store/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Ulcerative Colitis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Ulcerative Colitis Pipeline Report
• Coverage: Global
• Key Ulcerative Colitis Companies: Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
• Key Ulcerative Colitis Pipeline Therapies: Etrasimod, Description, Ivarmacitinib, Cobitolimod, TREMFYA, Omilancor, PRA023, Remestemcel-L, ritlecitinib, brepocitinib, ABBV-668, TEV-48574, SOR102, and others.

Dive deep into rich insights for drugs used for Ulcerative Colitis treatment; visit @ https://www.delveinsight.com/report-store/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Ulcerative Colitis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Ulcerative Colitis Pipeline Therapeutics
6. Ulcerative Colitis Pipeline: Late-Stage Products (Phase III)
7. Ulcerative Colitis Pipeline: Late-Stage Products (Phase III)
8. Ulcerative Colitis Pipeline: Mid-Stage Products (Phase II)
9. Ulcerative Colitis Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.